Financing channel feed

Co­manche se­cures $75M to test preeclamp­sia siR­NA in PhII, adds Scott Got­tlieb to board

Last year
Startups

Kyver­na Ther­a­peu­tics files for IPO as au­toim­mune CAR-T space heats up

Last year
Startups
Cell/Gene Tx

Dis­co de­buts with €20M seed round to ad­vance sur­faceome-based plat­form, with sup­port from Ab­b­Vie

Last year
Startups

Mid-stage CNS biotech Al­to Neu­ro­science files for NYSE list­ing

Last year
Startups

Ex­clu­sive: Au­toim­mune CAR-T biotech Kyver­na Ther­a­peu­tics is con­sid­er­ing an IPO next month

Last year
Startups
Cell/Gene Tx

Dyne clos­es $345M pub­lic of­fer­ing a week af­ter ear­ly pos­i­tive da­ta for dy­s­tro­phy drugs

Last year
R&D

Prax­is prices $150M pub­lic stock of­fer­ing ahead of four topline neu­ro read­outs in 2024

Last year

Blue­bird is still look­ing for more fi­nanc­ing as it brings sick­le cell ther­a­py to mar­ket: #JPM24

Last year
Cell/Gene Tx

CNS biotech My­robal­an Ther­a­peu­tics rais­es $24M Se­ries A to en­ter the clin­ic

Last year
Startups
China

Health­care gi­ant Gri­fols ac­cused of ma­nip­u­lat­ing fi­nances by short sell­er Gotham City, stock plum­mets 

Last year
Pharma

Il­lu­mi­na re­ports stronger-than-ex­pect­ed growth, in­di­cates Grail di­vesti­ture still in ear­ly stages: #JPM24

Last year

RTW, Bay­er back Cy­to­ki­net­ics-al­lied Ji Xing Phar­ma­ceu­ti­cals with $162M: #JPM24

Last year
China
Pharma

Ul­tragenyx nears $50M Se­ries A for its Alzheimer's gene ther­a­py spin­out: #JPM24

Last year
Cell/Gene Tx

El­liot­t's Marc Stein­berg sees more health­care in­vest­ments for the some­times-ac­tivist firm this year: #JPM24

Last year
People

Gene edit­ing com­pa­ny Metageno­mi sub­mits IPO pa­per­work in third planned biotech list­ing of 2024

Last year
Startups
Cell/Gene Tx

Ar­riVent files for IPO, rais­ing funds as it takes PhI­II can­cer drug through tri­al

Last year
Startups

Psy­che­del­ic-as­sist­ed drug de­vel­op­er MAPS PBC nabs $100M, re­names to Lykos Ther­a­peu­tics

Last year
Startups

Claris rais­es $57M in Se­ries A as it awaits key tri­al read­out on eye drug

Last year
Startups
R&D

4BIO pulls De­vel­op­ment Bank of Japan to dip its toes in­to UK life sci­ence by back­ing lat­est fund

Last year
Deals
R&D

Bei­jing on­col­o­gy biotech Avi­s­tone rais­es $140M Se­ries B for com­mer­cial­iza­tion in Chi­na, ex­pan­sion in­to US

Last year
China

An­oth­er day, an­oth­er ADC: On­Cusp se­cures $100M Se­ries A from No­vo, Or­biMed and oth­ers to run PhI tri­al

Last year
Startups
China

ARCH-backed im­munol­o­gy com­pa­ny HI-Bio rais­es $95M as it push­es to­ward late-stage stud­ies

Last year

As the biotech fund­ing game changed, TCGX al­tered course — and now they’re back with $1B for round two

Last year
Bioregnum

Trail­ing No­var­tis and Eli Lil­ly, ra­dio­phar­ma­ceu­ti­cals start­up Full-Life Tech­nolo­gies nabs $63M to test new PS­MA drug

Last year
China
Manufacturing
First page Previous page 20212223242526 Next page Last page
A service from the Financial Times